Alert: Fraudulent Job Notice

Welcome to Astellas Pharma Canada, Inc.

Astellas Pharma Canada, Inc. is committed to providing patients, customers, community and employees with a bright future by changing tomorrow. This commitment is made possible because we are a different kind of pharmaceutical company. Headquartered in Markham, Ontario, Astellas Pharma Canada, Inc. is recognized as the first Japanese pharmaceutical company in Canada.

In 2019, for the fourth consecutive year, Astellas Pharma Canada was named to the List of Best Workplaces™ in Canada by the Great Place to Work® Institute. For the first time ever, Astellas Pharma Canada was named to the 2019 Great Place to Work® List of Best Workplaces™ for Inclusion and Giving Back. The company was also featured on the 2019 Great Place to Work® List of Best Workplaces™ for Women – the fourth consecutive year the organization has received this recognition.

About Astellas in Canada

Read the Americas FY17 CSR Report


Topics
  • Learn more about our mission, corporate values and unique history.
  • Read about how Astellas employees are making a difference in the community.
  • Astellas is committed to providing patients and physicians with important information they need to manage their health and the health of their patients.
  • Learn about the various funding programs available to the Canadian medical community.
Press Releases
Astellas Pharma Canada named a Great Place to Work® for the fourth consecutive year
April 29, 2019
Astellas Pharma Canada, Inc. named to the 2019 List of Best Workplaces™ for Inclusion
January 15, 2019
Health Canada Approves XTANDI® (enzalutamide) - the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
January 14, 2019
Astellas and the Movember Foundation Put Prostate Cancer First with #flashyourstache
November 21, 2018
Astellas Pharma Canada partners with Wish of a Lifetime Canada to fulfill the lifelong wishes of Canadian seniors
July 05, 2018
Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World
June 12, 2018
Astellas Pharma Canada Scores a "Hat Trick" as a Great Place to Work®
April 26, 2018
Astellas Names Percival Barretto-Ko as President, Americas Operations
March 15, 2018
Phase 3 PROSPER Trial Shows XTANDI� (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
February 6, 2018
Astellas Appoints Kenji Yasukawa as President and CEO
January 31, 2018
Astellas Announces Leadership Changes in Canada and U.S.
January 8, 2018
Astellas, the Movember Foundation and the Toronto Maple Leafs Enter a Power Play with #pucks4prostate
November 1, 2017
Astellas Pharma Canada Partners with the Abilities Centre for Eighth Annual Changing Tomorrow Day
October 25, 2017
$100,000 in Grant Funding Awarded to Support Transformative Thinking in Transplantation
September 27, 2017